Clinical Trial Update: Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial at Stanford evaluating Personalized Accelerated Chemoradiation (PACER) for lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• PACER (Personalized Accelerated Chemoradiation)

Snippet

Sponsor: Stanford University | Conditions: Lung Cancer | Phase 1 | Status: RECRUITING